Fundraising Fox
Sparrow Pharma
Portland, US · Founded 2013 · Delaware corporation · 17 employees on LinkedIn · 5 known investors
Find your way into Sparrow Pharma
Sign up to see every warm intro you have to Sparrow Pharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Sparrow Pharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for cardiometabolic disease. Its lead program, clofutriben, is an HSD-1 inhibitor being evaluated in a Phase 2b trial for patients with inadequately controlled type 2 diabetes driven by elevated cortisol.
Founders & leadership
Board
Investors · 5
How we know: OrbiMed's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: RiverVest Venture Partners's portfolio page · Not right? Tell us
How we know: US Venture Partners's portfolio page · a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$73.3M disclosed across 4 rounds · 2018–2025
▶$61.8MraisedJul 2025 · 17 investors · PharmaceuticalsRule 506(b)
- Jonathan RootDirector
- Niall O'DonnellDirector
- Zach ScheinerDirector
- Klaus VeitingerDirector
- Nanna L?neborgDirector
- Peter ThompsonDirector
- Robert JacksExecutive Officer, Director
- Offering amount
- $121.4M
- Amount sold
- $61.8M
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedApr 2024 · 4 investors · PharmaceuticalsRule 506(b)
- Peter ThompsonDirector
- Jonathan RootDirector
- Klaus VeitingerDirector
- Niall O'DonnellDirector
- Robert JacksExecutive Officer, Director
- Offering amount
- $15.3M
- Amount sold
- $10M
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedJan 2021 · 15 investors · PharmaceuticalsRule 506(b)
- David KatzExecutive Officer
- Robert JacksExecutive Officer, Director
- Peter ThompsonDirector
- Klaus VeitingerDirector
- Offering amount
- $50.8M
- Amount sold
- $1.1M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$337.5KraisedJun 2020 · 10 investors · PharmaceuticalsRule 506(b)
- David Aaron KatzExecutive Officer, Director
- Offering amount
- $337.5K
- Amount sold
- $337.5K
- Minimum investment
- $10K
- Sales commissions
- $675
- Placement agents
- Exemplar Capital, LLC
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Companies working in the same space as Sparrow Pharma.
Frequently asked questions
- What does Sparrow Pharma do?
- Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for cardiometabolic disease. Its lead program, clofutriben, is an HSD-1 inhibitor being evaluated in a Phase 2b trial for patients with inadequately controlled type 2 diabetes driven by elevated cortisol.
- Who are Sparrow Pharma's investors?
- Sparrow Pharma's investors include OrbiMed, RA Capital, RiverVest Venture Partners, US Venture Partners, Forbion.
- How much funding has Sparrow Pharma raised?
- Sparrow Pharma has disclosed $73.3M raised across 4 rounds.
- Where is Sparrow Pharma headquartered?
- Sparrow Pharma is headquartered in Portland, US.